Researchers from Queen Mary University of London have developed and validated a new tool that could help GPs detect ovarian cancer earlier and improve patient outcomes cost-effectively.
Despite evidence suggesting the safety of hormone therapy for patients with a history of low-grade endometrial or epithelial ovarian cancer, a new survey shows that many gynecologists and some gynecologic oncologists are still uncomfortable prescribing the therapy for this patient population.
Research reveals FSHB and FSH as key biomarkers for endometrioid ovarian cancer, offering insights into early detection and potential drug repurposing.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
